(Q34607739)

3 August 2017

1 reference

title

Medroxyprogesterone acetate in the management of cancer cachexia (English)

1 reference

medroxyprogesterone acetate

3 August 2017

main subject

1 reference

Clelia Madeddu

1

1 reference

3 August 2017

Antonio Macciò

2

1 reference

3 August 2017

Filomena Panzone

3

1 reference

3 August 2017

Francesca Maria Tanca

4

1 reference

3 August 2017

Giovanni Mantovani

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

10

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1359-1366

1 reference

Novel approaches to the treatment of cachexia.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

The syndrome of cardiac cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

The metabolic basis of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Cachexia: a new definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Cytokines and Their Role in the Pathophysiology of Cancer Cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Neurochemical mechanisms for cancer anorexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

The role of TNF alpha in adipocyte metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Evidence for the involvement of interleukin 6 in experimental cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Pharmacological profile of progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Classification and pharmacology of progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Managing cancer-related anorexia/cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

The science of megestrol acetate delivery: potential to improve outcomes in cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

A review of the drug treatment of cachexia associated with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902960162

Effect of progestins with different glucocorticoid activity on bone metabolism

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1111/J.1365-2265.2007.03059.X

Identifiers

DOI

10.1517/14656560902960162

1 reference

3 August 2017

1 reference